Alzheimer's Breakthroughs Risk Failure Without Global Healthcare Reform

Two new drugs have arrived in the clinic with real promise. Lecanemab and donanemab, both monoclonal antibodies designed to slow the progression of Alzheimer's disease, have now been approved for use. Blood tests that can detect the disease earlier have come along with them. For the first time in decades, there is something that works—not a cure, but a measurable slowing of decline that rivals what doctors have achieved with cancer medications, treatments for rheumatoid arthritis, and multiple sclerosis therapies. Forty leading Alzheimer's researchers, writing in The Lancet, say this moment could reshape how the disease is managed. But they also say it will not happen by accident.

Alzheimer's accounts for roughly seven of every ten dementia cases and stands as a major driver of disability worldwide, carrying enormous weight both for families and for healthcare budgets. The new antibody treatments represent a genuine shift in what medicine can offer. The efficacy is there. The science has moved. Yet the researchers warn that without rapid, coordinated change across healthcare systems, public policy, and how society thinks about the disease, these tools will reach only some patients—likely the ones who already have access to good care and money.

The obstacle is not the drugs themselves. It is everything around them. The medications are expensive. The testing protocols are complex. Many healthcare systems are already stretched thin, with too few dementia specialists and general practitioners who lack training in the newer diagnostic approaches. Behavioral symptoms—the agitation, the confusion, the personality changes that often accompany cognitive decline—remain poorly managed in many settings. Resources for psychosocial care, the kind of steady, unglamorous support that patients and families desperately need, are scarce. Without reform, these new treatments risk becoming another advance that widens the gap between those who can access cutting-edge medicine and those who cannot.

There is also a prevention angle emerging. Brain Health Services are beginning to identify people at high risk of developing Alzheimer's and offering them personalized interventions. This is valuable work. But most Alzheimer's cases occur in people with low or normal risk profiles, which means individual screening and treatment alone will never be enough. The researchers call for population-wide measures—better urban design that encourages physical activity, restrictions on alcohol and sugary drinks, the kind of structural changes that shift risk across entire communities. These are not glamorous interventions. They do not require a prescription. But they may prevent more cases than any drug ever will.

Professor Giovanni Frisoni of the University of Geneva, who led the expert series, framed the challenge plainly. The science is moving fast. Blood tests, biological drugs, prevention programs—all of it is pushing care into new territory. But the old needs of patients remain. Doctors will need to master not just the new diagnostics and medications, but also the decades of accumulated knowledge about managing behavioral disorders, using imaging and laboratory tools skillfully, and providing the kind of psychosocial support that helps people live with the disease. This requires a concerted effort across society—healthcare providers, policymakers, and communities working together. Without it, the breakthrough drugs will sit on shelves while patients who could benefit from them never reach a clinic equipped to prescribe them.